Year: 2010
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: To identify antemortem CSF diagnostic biomarkers that can potentially distinguish between the 2 main causes of frontotemporal lobar degeneration (FTLD), i.e., FTLD with TDP-43 pathology (FTLD-TDP) and FTLD with tau pathology (FTLD-tau). METHODS: CSF samples were collected antemortem from 23 patients with FTLD with known pathology to form a autopsy cohort as part of a comparative biomarker study that additionally included 33 living cognitively normal subjects and 66 patients with autopsy-confirmed Alzheimer disease (AD). CSF samples were also collected from 80 living patients clinically diagnosed with frontotemporal dementia (FTD). Levels of 151 novel analytes were measured via a targeted multiplex panel enriched in neuropeptides, cytokines, and growth factors, along with levels of CSF biomarkers for AD. RESULTS: CSF levels of multiple analytes differed between FTLD-TDP and FTLD-tau, including Fas, neuropeptides (agouti-related peptide and adrenocorticotropic hormone), and chemokines (IL-23, IL-17). Classification by random forest analysis achieved high sensitivity for FTLD-TDP (86%) with modest specificity (78%) in the autopsy cohort. When the classification algorithm was applied to a living FTD cohort, semantic dementia was the phenotype with the highest predicted proportion of FTLD-TDP. When living patients with behavioral variant FTD were examined in detail, those predicted to have FTLD-TDP demonstrated neuropsychological differences vs those predicted to have FTLD-tau in a pattern consistent with previously reported trends in autopsy-confirmed cases. CONCLUSIONS: Clinical cases with FTLD-TDP and FTLD-tau pathology can be potentially identified antemortem by assaying levels of specific analytes that are well-known and readily measurable in CSF.
Source: Neurology
Authors: W.T. Hu, A. Chen-Plotkin, M. Grossman, S.E. Arnold, C.M. Clark, L.M. Shaw, L. McCluskey, L. Elman, H.I. Hurtig, A. Siderowf, V.M.-Y. Lee, H. Soares, J.Q. Trojanowski
Institutions: University of Pennsylvania, Pfizer (United States)
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: frontotemporal lobar degeneration, cerebrospinal fluid biomarkers, FTLD-TDP, FTLD-tau, frontotemporal dementia, TDP-43 pathology, tau pathology, Fas, neuropeptides, agouti-related protein, ACTH, chemokines, IL-23, IL-17, semantic dementia, behavioral variant frontotemporal dementia, differential diagnosis, Alzheimer's disease, antemortem diagnosis
Open Access status: bronze
Awards: G159687979, G2233657166, G2287182814, G2801376415, G3146424788, NIA Core Center to Build Neurodegenerative Disease Research Faculty At Penn, Parkinson's Disease and Dementia, Alzheimer's Disease Core Center, A Collaborative Center for the PD Neuroprotection Trial, Molecular substrates of aging and neuron death, G4491021986, Conceptual Processing in Alzheimer's Disease, Frontotemporal Dementias: Genotypes and Phenotypes, G5279807026, Parkinsons disease and research consent capacity, G553888402, G5610321346, Alzheimer's Disease Neuroimaging Initiative, Alzhelmer's Disease Drug Development Program, Amyloid Imaging, VMCI, and Analysis for ADNI, G8110056493, G8390535266, G8720365894, Neural Basis of Generalized Quantifiers, G9000060319, Frontotemporal Dementia: Genes, Images, and Emotions
OpenAlex ID: W2002662877
